论文部分内容阅读
Crenolanib besylate,a type Ⅰ pan-FLT3 inhibitor,to demonstrate clinical activity in multiply relapse
【作 者】
：
【机 构】
：
The University of Texas MD Anderson Cancer Center,Houston,TX
【出 处】
：
2016年临床肿瘤学新进展学术研讨会
【发表日期】
：
2016年5期
其他文献
Cabazitaxel vs docetaxel in chemotherapy-naive(CN)patients with metastatic castrationresistant prost
会议
ESPAC-4:A multicenter,international,open-label randomized controlled phase Ⅲ trial ofadjuvant combin
会议
A randomized phase Ⅲ trial between adjuvant docetaxel and surveillance after radical prostatectomy f
会议
Quality of life(QOL)analysis from CHAARTED:Chemohormonal androgen ablation randomized trial in prost
会议
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized pros
会议
Overall survival(OS)in METEOR,a randomized phase 3 trial of cabozantinib(Cabo)versus everolimus(Eve)
会议
Atezolizumab(atezo)as first-line(1L)therapy in cisplatin-ineligible locally advanced/metastatic urot
会议
Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cy
会议